Arkolith/Insider Trading/XERS/Form 4

McCulloch Kevin

See RemarksXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Mar 16, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 12, 2026Option exercise(M)49K$4.09$200K1.8M
Mar 12, 2026Option exercise(M)4$3.94$161.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 12, 2026Option exercise(M)4$3.94$1680K
Mar 12, 2026Option exercise(M)49K$4.09$200K44K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002031695-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML